hyperpituitarism: Disease of the glandular, anterior portion of the pituitary (pituitary gland, anterior) resulting in hypersecretion of adenohypophyseal hormones such as growth hormone; prolactin; thyrotropin; luteinizing hormone; follicle stimulating hormone ; and adrenocorticotropic hormone. Hyperpituitarism usually is caused by a functional adenoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
249 |
4. Check minimum number of eventsNone |
249 |
5. Include endpointsNone |
249 |
6. Filter based on genotype QC (FinnGen only) |
238 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E22
- Name in latin
- Acromegalia
Similar endpoints
↥List of similar endpoints to
Acromegaly and pituitary gigantism
based on the number of shared cases.
Similar with more cases:
- Hyperfunction of pituitary gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1586 | 866 | 703 |
| Only index persons | 1180 | 661 | 519 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 48.81 | 49.54 | 47.84 |
| Only index persons | 45.67 | 45.99 | 45.26 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 238 | 145 | 93 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | 45.51 | 43.33 | 48.90 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 249
- Matched controls
- 2490
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
+∞
293.2
220
*
H02AB09
ATC
hydrocortisone; systemic
141.6
225.3
115
15
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
+∞
184.0
153
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
1204.4
140.3
124
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
104.8
93
*
H01CB02
ATC
octreotide; parenteral
+∞
54.2
50
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
49.7
46
*
H01CB03
ATC
lanreotide; parenteral
+∞
46.3
43
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
43.0
40
*
N04BC06
ATC
cabergoline; oral
244.1
41.2
41
*
ZXC86
NOMESCO Finland
Use of endoscopic device
223.1
37.9
38
*
2530A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Acromegaly and gigantism[ACROMEGALIA]
+∞
36.3
34
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
9.8
32.7
41
49
UJF32
NOMESCO Finland
Coloscopy
4.6
31.4
116
394
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
30.9
29
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
12.0
27.4
29
27
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.5
25.4
80
236
25300
ICD-8 Finland
Diseases of pituitary gland, Aeromegalia
+∞
23.3
22
*
H03AA01
ATC
levothyroxine sodium; systemic
3.9
23.1
100
368
G02CB01
ATC
bromocriptine; systemic
25.1
22.3
31
14
E22.9
ICD-10 Finland
Hyperfunction of pituitary gland, unspecified
+∞
21.1
20
*
AA4CM
NOMESCO Finland
Extensive MRI examination of sella turcica with 3 Tesla magnet
+∞
21.1
20
*
102
Kela drug reimbursment
Diabetes insipidus
+∞
20.1
19
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
27.3
20.0
27
11
AA4BG
NOMESCO Finland
MRI examination of sella turcica with high intensity magnet
216.5
19.9
20
*
WVA30, ,
SPAT
7.4
19.6
30
45
ZXE20
NOMESCO Finland
More than three and less than five hours
4.1
18.3
61
184
WX408
NOMESCO Finland
General anesthesy, balanced
3.3
17.6
100
425
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
4.4
16.4
46
121
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
+∞
15.8
15
*
2542
FHL
Transasal hypophysectomy
+∞
15.8
15
*
ZXC95
NOMESCO Finland
Use of surgical navigator
25.6
14.0
19
8
XCK00
NOMESCO Finland
Perimetry
5.1
13.7
31
68
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.1
13.7
41
113
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
13.7
13
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
13.7
13
*
D44.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pituitary gland
+∞
13.7
13
*
AA4DG
NOMESCO Finland
Very extensive MRI examination of sella turcica with high intensity magnet
+∞
13.7
13
*
WX402
NOMESCO Finland
General anaesthesia
3.0
12.7
72
299
M14.5*E22.0
ICD-10 Finland
Arthropathy associated with acromegaly
+∞
12.6
12
*
G47.3
ICD-10 Finland
Sleep apnoea
2.8
12.6
82
367
UJF30
NOMESCO Finland
Ileoscopy through colon
3.7
12.5
44
136
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
6.3
12.0
21
36
N04BC01
ATC
bromocriptine; oral
+∞
11.5
11
*
T99
ICPC
Endocr/metab/nutrit disease other
14.8
11.2
18
13
D12.2
ICD-10 Finland
Benign neoplasm: Ascending colon
9.5
11.0
22
25
E21.0
ICD-10 Finland
Primary hyperparathyroidism
+∞
10.5
10
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.4
9.8
107
602
D352, E220,
ICD-10 Finland
+∞
9.4
9
*
H01AX01
ATC
pegvisomant; parenteral
+∞
9.4
9
*
E22
ICD-10 Finland
Hyperfunction of pituitary gland
+∞
9.4
9
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
4.9
9.2
21
46
WX882
NOMESCO Finland
High dependency care
12.1
9.2
16
14
-50
ICPC
Medication/prescr/renewal
5.1
8.7
19
40
WX110
NOMESCO Finland
Infiltration anesthesia
2.5
8.6
191
1418
K07.25
ICD-10 Finland
Anomalies of dental arch relationship
20.9
8.6
12
6
T73
ICPC
Neoplasm endocrine other/unspecified
93.1
8.5
9
*
E23.09
ICD-10 Finland
Pituitary insufficiency NOS
+∞
8.4
8
*
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
8.4
8
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.5
8.0
63
302
AA1AD
NOMESCO Finland
CT of head and brain
2.3
8.0
76
397
K57.3
ICD-10 Finland
Diverticular disease of large intestine without perforation or abscess
2.5
7.9
57
262
121
Kela drug reimbursment
Severe hypofunction of sexual glands
9.9
7.9
15
16
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
7.7
48
205
R06.5
ICD-10 Finland
Mouth breathing
3.2
7.7
33
115
N91.1
ICD-10 Finland
Secondary amenorrhoea
25.9
7.6
10
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
7.5
65
324
22620
ICD-8 Finland
Benign neoplasm of endocrine glands, Pituitary gland and craniopharyngeal duct (pouch)
+∞
7.3
7
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.8
7.0
22
62
D12.8
ICD-10 Finland
Benign neoplasm: Rectum
4.2
6.7
18
45
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
71.6
6.5
7
*
JFA15
NOMESCO Finland
Endoscopic polypectomy in colon
3.6
6.4
22
66
UDM02
NOMESCO Finland
Sinoscopy
6.3
6.4
16
27
E23.05
ICD-10 Finland
Lack of TSH
+∞
6.3
6
*
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
+∞
6.3
6
*
H01AC01
ATC
somatropin; parenteral
+∞
6.3
6
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
6.3
6
*
E89.30
ICD-10 Finland
Postprocedural hypopituitarism
+∞
6.3
6
*
E220, D352,
ICD-10 Finland
+∞
6.3
6
*
Y28
ICPC
Limited function/disability (Y)
+∞
6.3
6
*
SPAT1254
SPAT
Administration of medicine
2.5
6.2
41
180
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
6.2
78
450
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
6.1
110
718
ZXD10
NOMESCO Finland
Scheduled procedure
2.0
6.0
97
609
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.3
6.0
54
272
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
165
176
25.83
158.38
6.0
1.7
358.29
402.61
nmol/l
1.51
156
163
61
52
15.21
62.51
2.5
1.1
7.80
7.63
u/l
0.03
49
42
47
89
6.28
24.81
2.1
1.3
20.82
24.49
iu/l
0.28
35
77
29
16
20.33
19.63
1.2
1.9
—
—
—
0
0
168
930
3.48
19.36
8.1
5.6
1.22
1.22
mmol/l
0.33
137
794
157
850
3.29
18.46
7.3
4.8
1.22
1.21
mmol/l
0.49
147
766
26
13
22.14
18.17
1.0
1.6
6.62
16.95
mu/l
1.85
26
13
27
24
12.47
15.20
2.0
1.3
0.36
0.34
nmol/l
0.05
15
19
219
1554
4.40
14.81
8.0
3.9
15.59
14.75
pmol/l
5.04
214
1401
26
49
5.81
13.56
3.2
1.4
173.77
259.36
pmol/l
2.15
26
44
179
1169
2.89
12.99
7.7
3.9
6.49
6.67
mmol/l
0.68
169
1081
55
196
3.32
12.54
5.3
6.9
15.57
12.26
kpa
2.01
50
187
55
199
3.26
12.21
5.3
6.9
0.37
1.16
mmol/l
0.85
43
157
90
538
2.05
6.52
1.7
1.6
1.24
1.34
mmol/l
0.55
80
457
47
217
2.44
6.39
6.5
6.0
104.32
104.18
mmol/l
0.07
47
217
133
925
1.94
6.15
2.8
2.3
—
—
—
0
0
126
868
1.91
5.92
12.5
11.3
1.09
1.22
inr
1.60
40
252
13
21
6.47
5.46
1.2
1.2
—
—
—
0
0
77
465
1.95
5.25
2.4
2.1
—
—
—
0
0
38
185
2.24
4.55
3.1
3.0
—
—
—
0
0
16
51
3.28
4.29
2.1
1.5
—
—
—
0
0
188
1570
1.81
3.91
8.9
6.8
76.70
77.55
u/l
0.13
180
1457
216
1894
2.06
3.74
7.1
4.6
1.33
1.87
mu/l
11.95
205
1725
77
520
1.70
3.46
2.5
3.1
836.59
1052.01
ng/l
0.53
72
436
103
764
1.59
3.15
1.9
1.9
97.40
97.55
pmol/l
0.01
55
365
5
5
10.17
2.99
1.2
1.2
131.42
82.86
ug/l
—
5
5
89
645
1.59
2.96
5.9
2.9
2.37
2.34
mmol/l
0.95
81
570
129
1038
1.50
2.59
6.6
5.6
10.44
10.87
umol/l
0.43
124
978
211
1901
1.72
2.47
7.5
5.3
40.22
39.48
mmol/mol
0.50
205
1783
219
2005
1.77
2.26
5.4
4.3
5.82
5.89
mmol/l
0.44
213
1834
71
528
1.48
2.01
3.7
2.7
0.76
0.33
e6/l
0.65
56
383
43
286
1.61
2.00
2.9
2.0
11.70
14.07
umol/l
2.06
43
268
7
21
3.40
1.98
1.0
1.2
—
—
nmol/l
—
0
0
21
114
1.92
1.94
1.4
1.4
—
—
—
0
0
87
678
1.44
1.92
3.5
2.8
—
—
—
0
0
139
1179
1.41
1.89
9.4
9.2
3.85
3.96
e9/l
0.23
122
1032
6
17
3.59
1.85
2.2
1.9
1.82
3.11
nmol/l
—
6
17
8
29
2.82
1.80
1.3
1.4
—
—
—
0
0
59
436
1.46
1.71
2.1
2.0
3.06
3.32
mg/l
0.34
52
375
8
31
2.63
1.67
2.1
1.5
—
—
—
0
0
14
71
2.03
1.57
1.2
1.6
—
—
—
0
0
118
1001
1.34
1.48
5.1
4.6
0.00
0.00
estimate
-0.00
33
176
119
1013
1.33
1.45
3.7
3.4
0.00
0.00
estimate
-0.00
33
168
46
336
1.45
1.41
3.4
2.8
2.45
2.43
mmol/l
0.28
39
299
117
998
1.33
1.39
3.7
3.4
0.00
0.00
estimate
-0.00
36
188
6
23
2.65
1.37
1.5
1.1
—
—
—
0
0
107
904
1.32
1.35
3.2
2.5
96.54
108.50
ug/l
0.47
98
829
70
555
1.36
1.35
3.7
3.7
0.06
0.00
estimate
0.49
33
171
23
349
0.62
1.34
1.7
1.4
—
—
—
0
0
5
18
2.81
1.29
1.0
1.0
—
—
—
0
0
5
18
2.81
1.29
1.0
1.0
—
—
—
0
0
95
794
1.32
1.28
3.8
3.5
—
—
—
0
0
40
291
1.45
1.26
3.1
2.5
1.82
3.01
e6/l
0.63
23
146
170
1544
1.32
1.22
4.3
3.9
12.86
10.84
mm/h
1.04
161
1411
12
208
0.56
1.18
2.0
1.7
—
—
—
0
0
5
22
2.30
1.04
1.2
1.0
—
—
—
0
0
89
757
1.27
1.02
3.6
3.3
39.55
36.19
ng/l
0.08
69
494
16
100
1.64
0.99
1.7
2.6
0.25
0.21
e6/l
0.11
16
95
16
243
0.63
0.96
2.1
2.0
—
—
—
0
0
55
443
1.31
0.95
1.6
1.5
21.93
20.96
nmol/l
0.17
47
375
28
202
1.44
0.94
1.8
4.7
243.36
243.04
u/l
0.00
28
196
75
635
1.26
0.88
2.5
2.4
62.26
55.37
u/l
0.32
70
579
206
1953
1.32
0.88
19.4
11.3
85.19
83.23
ml/min/173m2
0.69
198
1597
8
44
1.84
0.86
1.1
1.2
—
—
—
0
0
8
47
1.73
0.81
2.3
1.2
—
—
—
0
0
5
96
0.51
0.80
3.0
2.4
37.20
42.61
u/l
—
5
85
0
24
0.00
0.79
0.0
2.7
—
—
—
0
0
9
54
1.69
0.75
1.1
1.9
—
—
—
0
0
7
39
1.82
0.73
1.0
1.2
0.43
0.87
nmol/l
—
7
33
36
287
1.30
0.69
1.6
1.7
—
—
—
0
0
16
224
0.69
0.68
2.0
1.9
—
—
—
0
0
5
28
1.80
0.66
1.2
1.3
—
—
—
0
0
42
344
1.27
0.66
5.1
3.8
48.37
337.70
ng/l
1.64
30
255
39
319
1.26
0.62
3.1
2.3
2.56
0.98
e6/l
0.38
23
172
8
52
1.56
0.60
1.3
1.3
—
—
—
0
0
53
453
1.22
0.58
1.5
1.3
1.76
1.37
u/ml
0.12
14
122
6
36
1.68
0.57
1.5
1.4
—
—
—
0
0
6
36
1.68
0.57
1.5
4.1
61.17
58.97
%
—
6
36
215
2081
1.24
0.53
18.2
12.1
24.28
21.82
mg/l
0.52
173
1598
7
107
0.64
0.50
1.0
1.3
—
—
—
0
0
52
452
1.19
0.48
1.9
1.7
1.30
0.98
mg/l
0.33
44
345
8
116
0.68
0.47
1.0
1.1
—
—
—
0
0
14
103
1.38
0.46
1.5
1.3
—
—
—
0
0
25
202
1.26
0.45
1.5
1.7
—
—
—
0
0
18
140
1.31
0.43
1.2
1.3
135.25
155.15
iu/ml
—
8
57
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
64
575
1.15
0.40
4.4
3.8
9.47
9.83
mg/mmol
0.03
47
361
7
104
0.66
0.40
1.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
2.1
—
—
—
0
0
0
18
0.00
0.40
0.0
2.1
—
—
—
0
0
0
18
0.00
0.40
0.0
2.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.5
—
—
—
0
0
5
35
1.44
0.39
1.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
4.1
—
74.77
—
0
19
235
2311
1.30
0.37
28.9
18.2
40.25
40.43
%
0.22
217
2174
24
199
1.23
0.36
1.5
1.6
—
—
—
0
0
9
71
1.28
0.36
1.4
1.4
—
—
—
0
0
9
123
0.72
0.36
1.2
1.9
—
—
—
0
0
34
392
0.85
0.36
1.4
1.7
443.55
466.57
pmol/l
0.27
29
335
6
42
1.44
0.36
1.2
1.6
—
—
—
0
0
20
243
0.81
0.35
7.5
6.4
—
—
—
0
0
6
45
1.34
0.34
1.2
1.6
—
—
—
0
0
34
384
0.87
0.29
1.1
1.3
42.98
35.70
iu/ml
—
9
136
21
177
1.20
0.28
2.1
2.2
0.20
0.22
g/l
0.78
21
163
38
339
1.14
0.27
1.6
1.6
1086.94
1190.79
nmol/l
0.29
31
245
8
66
1.22
0.27
2.3
1.8
—
—
—
0
0
9
76
1.19
0.25
1.3
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
7
58
1.21
0.18
1.3
1.1
—
2.78
—
0
10
5
69
0.72
0.17
2.0
1.4
—
—
—
0
0
8
71
1.13
0.16
2.3
2.0
—
—
—
0
0
6
78
0.76
0.16
1.7
1.9
—
—
—
0
0
41
387
1.07
0.11
1.5
1.5
—
—
—
0
0
5
46
1.09
0.09
1.4
1.3
—
38.47
—
0
8
5
46
1.09
0.09
1.2
1.4
—
—
—
0
0
36
380
0.94
0.09
1.1
1.3
1.29
9.88
u/ml
2.75
17
154
5
60
0.83
0.08
1.0
1.2
—
—
—
0
0
6
75
0.80
0.07
2.3
1.4
—
—
—
0
0
16
149
1.08
0.05
1.7
2.6
85.71
68.27
ml/min/173m2
—
7
62
46
447
1.04
0.04
3.7
3.9
23.21
21.60
%
0.25
21
187
10
93
1.08
0.02
5.4
2.4
0.59
0.67
%
—
10
93
13
129
1.01
0.00
1.2
1.3
—
32.33
—
0
6
10
103
0.97
0.00
1.5
1.6
—
—
—
0
0
33
334
0.99
0.00
2.2
2.7
0.51
0.72
ug/l
1.89
22
197
10
95
1.05
0.00
5.4
2.3
0.93
1.29
%
—
10
95
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
0.31
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
135
1350
1.00
-0.00
2.8
3.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
60
1.00
-0.00
1.3
1.4
—
2.71
—
0
13
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
-0.00
1.3
1.4
—
2.75
—
0
11
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
6
59
1.02
-0.00
1.3
3.6
—
2.72
—
0
9
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
62
0.97
-0.00
1.3
1.4
—
3.32
—
0
5
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_ACROMEG and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ACROMEG | 1.68 [1.25, 2.25] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.335 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 432 females with E4_ACROMEG died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ACROMEG | 1.62 [1.24, 2.12] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.029 |
During the follow-up period (1.1.1998 — 31.12.2019), 70 out of 350 males with E4_ACROMEG died.
Mortality risk
Mortality risk for people of age
years, who have E4_ACROMEG.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.147% | 0.274% |
| 5 | 0.885% | 2.148% |
| 10 | 2.427% | 5.483% |
| 15 | 4.67% | 9.864% |
| 20 | 8.7% | 16.301% |
Relationships between endpoints
↥Index endpoint: E4_ACROMEG – Acromegaly and pituitary gigantism
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data